In pancreatic cancer cells, the absence of GIPC promotes the depletion of the drug resistance molecule ABCG2 through exosome-mediated exocytosis or causes the sequestering of ABCG2 in vesicles, rendering it nonfunctional, which then makes cancer cells sensitive to gemcitabine 16. Here, GIPC1 is linked to pancreatic neoplasm.